Final results of a self-apposing paclitaxel-eluting stent for the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study

Christoph K. Naber; Stylianos A. Pyxaras; Holger Nef; Alexander J. IJsselmuiden; Carlo Briguori; Christian Schlundt; Joanna Wykrzykowska; Franz R. Eberli; Helge Möllmann; S. ren Galatius; Johannes Rieber; Philippe Commeau; Robert-Jan van Geuns; David Bouchez; Harald Mudra

doi:https://doi.org/10.4244/EIJY15M06_02

Final results of a self-apposing paclitaxel-eluting stent for the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study

Christoph K. Naber, Stylianos A. Pyxaras, Holger Nef, Alexander J. IJsselmuiden, Carlo Briguori, Christian Schlundt, Joanna Wykrzykowska, Franz R. Eberli, Helge Möllmann, S. ren Galatius, Johannes Rieber, Philippe Commeau, Robert-Jan van Geuns, David Bouchez, Harald Mudra

Research output: Contribution to journal › Article › Academic › peer-review

17 Citations (Scopus)

Abstract

Aims: We aimed to evaluate the long-term safety and efficacy of the STENTYS self-apposing paclitaxeleluting stent (STENTYS-PES) in bifurcation lesions in routine clinical practice. Methods and results: The primary endpoint of the study was the composite major adverse cardiac events (MACE: cardiac death, myocardial infarction, clinically driven target lesion revascularisation, or emergent bypass surgery) assessed at six months after enrolment. This was reported in 21 patients (10.1%), mainly due to clinically driven target lesion revascularisation (TLR). At 12 months, 27 patients experienced MACE (13.0%). Conclusions: The long-term results of OPEN II show that the STENTYS-PES is safe and effective in the treatment of all-comers with coronary bifurcation lesions.

Original language	English
Pages (from-to)	356-358
Journal	Eurointervention
Volume	12
Issue number	3
DOIs	https://doi.org/10.4244/EIJY15M06_02
Publication status	Published - 1 Jun 2016

Access to Document

https://doi.org/10.4244/EIJY15M06_02

Cite this

Naber, C. K., Pyxaras, S. A., Nef, H., IJsselmuiden, A. J., Briguori, C., Schlundt, C., Wykrzykowska, J., Eberli, F. R., Möllmann, H., Galatius, S. R., Rieber, J., Commeau, P., van Geuns, R.-J., Bouchez, D., & Mudra, H. (2016). Final results of a self-apposing paclitaxel-eluting stent for the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study. Eurointervention, 12(3), 356-358. https://doi.org/10.4244/EIJY15M06_02

@article{590b7071873148c7aad658ef2e9f48f7,

title = "Final results of a self-apposing paclitaxel-eluting stent for the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study",

abstract = "Aims: We aimed to evaluate the long-term safety and efficacy of the STENTYS self-apposing paclitaxeleluting stent (STENTYS-PES) in bifurcation lesions in routine clinical practice. Methods and results: The primary endpoint of the study was the composite major adverse cardiac events (MACE: cardiac death, myocardial infarction, clinically driven target lesion revascularisation, or emergent bypass surgery) assessed at six months after enrolment. This was reported in 21 patients (10.1%), mainly due to clinically driven target lesion revascularisation (TLR). At 12 months, 27 patients experienced MACE (13.0%). Conclusions: The long-term results of OPEN II show that the STENTYS-PES is safe and effective in the treatment of all-comers with coronary bifurcation lesions.",

author = "Naber, {Christoph K.} and Pyxaras, {Stylianos A.} and Holger Nef and IJsselmuiden, {Alexander J.} and Carlo Briguori and Christian Schlundt and Joanna Wykrzykowska and Eberli, {Franz R.} and Helge M{\"o}llmann and Galatius, {S. ren} and Johannes Rieber and Philippe Commeau and {van Geuns}, Robert-Jan and David Bouchez and Harald Mudra",

year = "2016",

month = jun,

day = "1",

doi = "https://doi.org/10.4244/EIJY15M06_02",

language = "English",

volume = "12",

pages = "356--358",

journal = "Eurointervention",

issn = "1774-024X",

publisher = "EuroPCR",

number = "3",

}

Naber, CK, Pyxaras, SA, Nef, H, IJsselmuiden, AJ, Briguori, C, Schlundt, C, Wykrzykowska, J, Eberli, FR, Möllmann, H, Galatius, SR, Rieber, J, Commeau, P, van Geuns, R-J, Bouchez, D & Mudra, H 2016, 'Final results of a self-apposing paclitaxel-eluting stent for the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study', Eurointervention, vol. 12, no. 3, pp. 356-358. https://doi.org/10.4244/EIJY15M06_02

TY - JOUR

T1 - Final results of a self-apposing paclitaxel-eluting stent for the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study

AU - Naber, Christoph K.

AU - Pyxaras, Stylianos A.

AU - Nef, Holger

AU - IJsselmuiden, Alexander J.

AU - Briguori, Carlo

AU - Schlundt, Christian

AU - Wykrzykowska, Joanna

AU - Eberli, Franz R.

AU - Möllmann, Helge

AU - Galatius, S. ren

AU - Rieber, Johannes

AU - Commeau, Philippe

AU - van Geuns, Robert-Jan

AU - Bouchez, David

AU - Mudra, Harald

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Aims: We aimed to evaluate the long-term safety and efficacy of the STENTYS self-apposing paclitaxeleluting stent (STENTYS-PES) in bifurcation lesions in routine clinical practice. Methods and results: The primary endpoint of the study was the composite major adverse cardiac events (MACE: cardiac death, myocardial infarction, clinically driven target lesion revascularisation, or emergent bypass surgery) assessed at six months after enrolment. This was reported in 21 patients (10.1%), mainly due to clinically driven target lesion revascularisation (TLR). At 12 months, 27 patients experienced MACE (13.0%). Conclusions: The long-term results of OPEN II show that the STENTYS-PES is safe and effective in the treatment of all-comers with coronary bifurcation lesions.

AB - Aims: We aimed to evaluate the long-term safety and efficacy of the STENTYS self-apposing paclitaxeleluting stent (STENTYS-PES) in bifurcation lesions in routine clinical practice. Methods and results: The primary endpoint of the study was the composite major adverse cardiac events (MACE: cardiac death, myocardial infarction, clinically driven target lesion revascularisation, or emergent bypass surgery) assessed at six months after enrolment. This was reported in 21 patients (10.1%), mainly due to clinically driven target lesion revascularisation (TLR). At 12 months, 27 patients experienced MACE (13.0%). Conclusions: The long-term results of OPEN II show that the STENTYS-PES is safe and effective in the treatment of all-comers with coronary bifurcation lesions.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84975809639&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/26060087

U2 - https://doi.org/10.4244/EIJY15M06_02

DO - https://doi.org/10.4244/EIJY15M06_02

M3 - Article

C2 - 26060087

SN - 1774-024X

VL - 12

SP - 356

EP - 358

JO - Eurointervention

JF - Eurointervention

IS - 3

ER -

Final results of a self-apposing paclitaxel-eluting stent for the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study

Abstract

Access to Document

Other files and links

Cite this